Valneva /zigman2/quotes/202377434/delayed FR:VLA -1.53% shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's /zigman2/quotes/203048482/delayed UK:AZN +1.57% in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.





